50 citations,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
14 citations,
July 2021 in “Reviews in endocrine and metabolic disorders” SARS-CoV-2, the virus causing COVID-19, can affect all endocrine organs and systems, altering their function and potentially leading to disorders. Factors like diabetes and obesity increase infection risk and severity. Understanding these effects is key for effective treatment.
5 citations,
December 2021 in “Physiological Research” Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.
April 2024 in “Cell death and disease” Long COVID causes various long-term health issues and needs better awareness and treatment.
January 2020 in “arXiv (Cornell University)” Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
1 citations,
September 2021 in “Advances in skin & wound care” SARS-CoV-2 might infect and multiply in skin tissue, possibly aiding in its transmission.
February 2023 in “Vaccines” COVID-19 may harm male reproductive health and lower testosterone levels, potentially affecting fertility and causing erectile dysfunction. More research is needed.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
1 citations,
February 2022 in “The Journal of Urology” Certain drugs like Dutasteride and Finasteride might help fight SARS-CoV-2 by increasing levels of a steroid called DHEA, which can protect the heart and increase nitric oxide to counteract the virus.
8 citations,
December 2022 in “Nature Reviews Endocrinology” Sex hormones' effects on COVID-19 are unclear and more research is needed to understand their potential as treatment.
The pandemic worsened mental health and healthcare access for middle-aged women, leading to negative changes in their lifestyle.
1 citations,
December 2022 in “BMC Public Health” Long-term effects of COVID-19 can vary over time and are more likely in certain age and gender groups, while race, income, and education levels have little to no impact. Ongoing medical care is needed due to potential complications.
10 citations,
February 2022 in “Epidemiologia” One-third of COVID-19 patients had long-term symptoms like hair loss and fatigue, with women, older individuals, blood group B, smokers, and those with more virus exposure at higher risk.
23 citations,
July 2021 in “International journal of laboratory hematology” An 84-year-old man developed severe anemia after his first COVID-19 vaccine shot, improved with treatment, and was advised against a second dose.
121 citations,
November 2020 in “Endocrine” Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.
21 citations,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
March 2022 in “Journal of clinical case studies reviews & reports” COVID-19 can cause different skin issues, including rashes and hair loss.
13 citations,
April 2023 in “Nature communications” Long COVID patients have more health issues than non-infected people.
5 citations,
May 2020 in “Journal of The American Academy of Dermatology” Hydroxychloroquine might help prevent COVID-19, but more research is needed.
70 citations,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
January 2023 in “International journal of sciences” Platelet-Rich Plasma therapy helped significantly in hair recovery for a hair loss condition after infection.
41 citations,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
23 citations,
September 2021 in “Frontiers in Cellular and Infection Microbiology” Testosterone's effects on COVID-19 are unclear and need more research.
19 citations,
November 2021 in “Reviews in endocrine and metabolic disorders” Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.
16 citations,
December 2021 in “Frontiers in Endocrinology” Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.
1 citations,
January 2024 in “Microorganisms” Mice with a virus similar to COVID-19 had skin damage, but a special treatment helped repair it.
1 citations,
October 2022 in “Current Dermatology Reports” COVID-19 and vaccines cause various skin reactions and highlight the need for dermatologists in managing these issues and addressing vaccine distribution disparities.
January 2023 in “International Journal of Dermatology and Venereology” Many people experienced hair loss after having COVID-19, with the worst cases in hospitalized patients, and some saw hair regrowth within six months.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.